Progression free survival according to risk group. Median progression free survival from initiation of second-line chemotherapy was 6.1 months (95% CI, 4.1–8.5) in the low-risk group, 3.4 months (95% CI, 2.3–5.4) in the intermediate-risk group, and 2.6 months (95% CI, 1.6–2.9) in the high-risk group.